预约演示
更新于：2026-10-16
Lanthanum carbonate
碳酸镧
更新于：2026-10-16
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-10-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式CH4LaO4 |
InChIKeyLIOPFGUJULMLEN-UHFFFAOYSA-N |
CAS号54451-24-0 |
关联
73
项与 碳酸镧 相关的临床试验EUCTR2019-003698-24-NL
Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
NCT04440696
To Evaluate the Tolerance, pd, and pk of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-center, Multi-dose, Give the Drug Multiple Time
JPRN-UMIN000039788
Effect of ferric citrate for recovery from fatigue, phosphate binding, and iron supplementation in hemodialysis patients with well-controlled parathyroid hormone. -comparison with lanthanum carbonate-
100 项与 碳酸镧 相关的临床结果
登录后查看更多信息
100 项与 碳酸镧 相关的转化医学
登录后查看更多信息
100 项与 碳酸镧 相关的专利（医药）
登录后查看更多信息
1,052
项与 碳酸镧 相关的文献（医药）2026-10-01Kidney Medicine
Effects of Lanthanum Carbonate on Whole-Body Phosphorus and Calcium Balance in Adults With Chronic Kidney Disease and Normophosphatemia
Article
作者: Nowak, Kristen L ; Oh, Ester ; You, Zhiying ; Hill Gallant, Kathleen M ; Struemph, Taylor ; Schwartz, Gregory G ; Levi, Moshe ; Chonchol, Michel ; Jovanovich, Anna ; Marden, Tyson J
Rationale & Objective:
Greater serum phosphorus is associated with cardiovascular disease in those with chronic kidney disease (CKD). However, the utility of phosphorus lowering in nondialysis-requiring CKD is not clear. The effects of noncalcium-based phosphate binders on phosphorus and calcium balance in nondialysis-requiring CKD are unknown. Our objective was to determine phosphorus and calcium balance in normophosphatemic adults with CKD 3b-4 after 12 weeks of treatment with lanthanum carbonate or placebo.
Study Design:
Prospective, randomized, controlled, double-blind clinical trial.
Setting & Participants:
A subset of 15 adults with CKD 3b-4 and serum phosphorus levels within normal limits who participated in a 12-week parallel-arm, randomized controlled trial of lanthanum carbonate compared with placebo on vascular function participated in this study extension.
Intervention:
At the end of 12 weeks, the subset of participants consumed a controlled diet (1,000 mg/day phosphorus and 800 mg/day calcium) for 9 days and continued their randomly assigned study drug (N = 7 lanthanum carbonate, N = 8 placebo). Fasting morning blood samples and all stool and urine were collected during a 48-hour inpatient clinical research center stay at the end of the 9-day controlled diet period.
Outcomes:
Phosphorus and calcium balance (mg/d) were determined by values averaged over the 48 hours inpatient clinical research center admission.
Results:
Mean age was 65 ± 8 (SD) years, and mean estimated glomerular filtration rate was 38 ± 14 (SD) mL/min/1.73m2. Whole-body phosphorus balance was lower with lanthanum carbonate compared with placebo (-131 ± 163 [SEM] vs 320 ± 141 mg/d, P = 0.05), as was calcium balance (-46 ± 115 [SEM] vs 410 ± 100 mg/d, P = 0.01), corresponding to lower intestinal absorption supported by the fecal calcium and phosphorus and net absorption results. Neither 24-hour urine calcium nor phosphorus output was significantly different between lanthanum carbonate and placebo, but 24-hour urine phosphorus output differed between lanthanum carbonate and placebo but was not significant (388 ± 60 vs 513 ± 56 mg/d, p=0.15).
Limitations:
Small sample size.
Conclusions:
Twelve weeks of treatment with the noncalcium-based phosphate binder, lanthanum carbonate, may reduce whole-body phosphorus balance as well as calcium balance among adults with stage 3b-4 CKD and normophosphatemia. Whether reduced phosphorus balance or calcium balance with lanthanum carbonate is associated with beneficial clinical outcomes in CKD warrants further investigation.
2026-08-01INTERNAL MEDICINE
Association between Phosphate Binders and Constipation in Patients Undergoing Chronic Hemodialysis: A Cross-sectional Study
Article
作者: Morozumi, Kunio ; Takahashi, Hiroshi ; Kondo, Chika ; Hori, Mayuko ; Takeda, Asami ; Maruyama, Shoichi
Objective Constipation, a clinical form of gut dysbiosis, is highly prevalent in patients undergoing hemodialysis. Patients with chronic kidney disease experience uremia-related changes in the gut environment. Dysbiosis reportedly leads to an atherosclerosis pathogenesis, and constipation is associated with several adverse clinical outcomes including cardiovascular disease and mortality. Phosphate binders, commonly prescribed to patients with end-stage renal disease, bind to non-phosphate molecules and may alter the gut microbiota, potentially leading to systemic effects unrelated to phosphate control, although the clinical evidence is limited. Methods This cross-sectional study included 293 outpatients undergoing hemodialysis at Masuko Memorial Hospital, Japan. Information about patient characteristics and medication usage was collected, and constipation was assessed using the original diagnostic criteria, incorporating both the Rome IV criteria and a history of laxative use. Results Of 293 participants, 152 (51.9%) were diagnosed with constipation and 60 (20.5%) had severe constipation. Lanthanum carbonate use was independently associated with a lower risk of constipation [adjusted odds ratio (aOR) 0.55, 95% confidence interval (CI) 0.32-0.94, p=0.029] and a lower risk of severe constipation (aOR 0.41, 95%CI 0.19-0.86; p=0.018), while precipitated calcium carbonate use was associated with a lower risk of severe constipation, independent of age and sex (aOR 0.48, 95%CI 0.26-0.89, p=0.021). Conclusion Our study highlights the association between specific phosphate binders and a lower risk of constipation. Accordingly, phosphate binders could be selected based on their positive effects on constipation in this patient population.
2026-06-01General Thoracic and Cardiovascular Surgery
Short-term lanthanum carbonate reduces calcification of cryopreserved aortic allografts in the young: A Porcine circulatory transplant model
Article
作者: Asahina, Hiromichi ; Lee, Yangsin ; Yamauchi, Haruo ; Ono, Minoru
OBJECTIVES:
Cryopreserved aortic allografts in pediatric patients have limited durability due to graft calcification, resulting in high rate of reoperations. Physiological hyperphosphatemia in the young, coupled with inflammatory responses against post-transplant allografts, accelerates allograft calcification in a rat model. We aimed to examine the anti-calcification effect of a phosphate binder, lanthanum carbonate, on aortic allografts in a growing porcine model with blood flow and pressure that resembled clinical settings.
METHODS:
Four-week-old male specific pathogen-free crossbred piglets were used as donors and recipients. The descending aortas harvested from 5 donors were divided, cryopreserved, and transplanted into the descending aorta of 10 recipient piglets. The lanthanum group received lanthanum carbonate (45 mg/kg/day for 1 week preoperatively and 4 weeks postoperatively; n = 5) and was compared to the control group (without lanthanum carbonate; n = 5). The conduits were explanted at 8 weeks and examined using von Kossa staining and for calcium content quantification by atomic absorption spectroscopy. The sera and femurs were also retrieved to analyze adverse events of lanthanum carbonate.
RESULTS:
In the lanthanum group, allograft medial calcification developed less frequently, and the calcium content of the allografts was significantly lower than that in controls (p = 0.009). Body weight, hematocrit levels, and femur mineral density did not differ significantly between the groups at 8 weeks.
CONCLUSIONS:
Our results suggest that short-term lanthanum carbonate administration may alleviate cryopreserved allograft calcification in young recipients, without adverse effects.
120
项与 碳酸镧 相关的新闻（医药）2026-10-15
100 项与 碳酸镧 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高磷血症 | 奥地利 | 2005-03-01 | |
| 高磷血症 | 比利时 | 2005-03-01 | |
| 高磷血症 | 保加利亚 | 2005-03-01 | |
| 高磷血症 | 丹麦 | 2005-03-01 | |
| 高磷血症 | 爱沙尼亚 | 2005-03-01 | |
| 高磷血症 | 芬兰 | 2005-03-01 | |
| 高磷血症 | 法国 | 2005-03-01 | |
| 高磷血症 | 匈牙利 | 2005-03-01 | |
| 高磷血症 | 冰岛 | 2005-03-01 | |
| 高磷血症 | 爱尔兰 | 2005-03-01 | |
| 高磷血症 | 意大利 | 2005-03-01 | |
| 高磷血症 | 拉脱维亚 | 2005-03-01 | |
| 高磷血症 | 立陶宛 | 2005-03-01 | |
| 高磷血症 | 卢森堡 | 2005-03-01 | |
| 高磷血症 | 马耳他 | 2005-03-01 | |
| 高磷血症 | 荷兰 | 2005-03-01 | |
| 高磷血症 | 挪威 | 2005-03-01 | |
| 高磷血症 | 斯洛伐克 | 2005-03-01 | |
| 高磷血症 | 斯洛文尼亚 | 2005-03-01 | |
| 高磷血症 | 西班牙 | 2005-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 慢性肾病 serum phosphorus | oxidative stress | vascular dysfunction | 54 | 衊齋蓋壓築膚夢襯齋膚(衊壓廠窪廠齋觸窪壓夢) = 鬱窪衊醖醖餘繭衊網艱 糧夢獵廠獵構網願衊構 (窪鏇遞築齋蓋襯糧選壓 ) | 不佳 | 2024-05-23 | ||
Placebo | 衊齋蓋壓築膚夢襯齋膚(衊壓廠窪廠齋觸窪壓夢) = 獵築鏇製築衊膚願鏇顧 糧夢獵廠獵構網願衊構 (窪鏇遞築齋蓋襯糧選壓 ) | ||||||
临床2期 | 慢性肾病 interleukin-6 | C-reactive protein | 127 | 襯築膚積網選鬱遞積網(襯艱憲鏇糧簾窪繭醖衊) = 製壓積壓憲糧廠憲簾廠 製遞簾憲簾鑰衊網艱蓋 (選獵築鹹構鏇淵願築膚 ) 更多 | 积极 | 2024-04-04 | ||
Placebo | 襯築膚積網選鬱遞積網(襯艱憲鏇糧簾窪繭醖衊) = 鏇淵顧蓋淵廠醖願顧網 製遞簾憲簾鑰衊網艱蓋 (選獵築鹹構鏇淵願築膚 ) 更多 | ||||||
临床1期 | - | 39 | (Lanthanum + Nicotinamide) | 窪廠繭獵壓蓋糧憲顧醖(廠醖願憲窪夢蓋壓艱醖) = 構廠積壓觸夢獵壓觸鏇 築膚選糧願襯鑰構遞鏇 (構糧壓淵構鹽醖膚窪襯, 繭顧簾獵繭齋鑰艱襯願 ~ 範淵淵觸艱餘觸鹽鬱衊) 更多 | - | 2024-02-23 | |
Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo) | 窪廠繭獵壓蓋糧憲顧醖(廠醖願憲窪夢蓋壓艱醖) = 窪醖鹹網襯襯範淵餘鹹 築膚選糧願襯鑰構遞鏇 (構糧壓淵構鹽醖膚窪襯, 衊觸醖鑰鹹構壓鏇廠廠 ~ 網顧醖蓋獵蓋醖壓範膚) 更多 | ||||||
N/A | 19 | (Lanthanum Carbonate (Fosrenol)) | 窪壓簾網繭選獵獵遞觸(糧鬱製窪蓋願鹹膚鏇遞) = 鏇鑰獵衊選積艱觸醖製 鏇遞簾艱憲網壓醖選蓋 (鑰衊鹽鹽鹹夢獵範鑰憲, 55.17) 更多 | - | 2023-09-21 | ||
placebo (Placebo) | 窪壓簾網繭選獵獵遞觸(糧鬱製窪蓋願鹹膚鏇遞) = 選網鹹構衊壓餘醖膚醖 鏇遞簾艱憲網壓醖選蓋 (鑰衊鹽鹽鹹夢獵範鑰憲, 53.84) 更多 | ||||||
临床4期 | 15 | 觸繭顧鹽廠糧壓壓築範(膚齋繭膚廠鹽繭憲壓襯) = 簾憲醖構廠窪繭廠範廠 襯淵齋範窪膚鏇鹽糧艱 (範鏇醖醖鑰範願廠繭鑰 ) | 不佳 | 2022-11-05 | |||
Placebo | 觸繭顧鹽廠糧壓壓築範(膚齋繭膚廠鹽繭憲壓襯) = 積夢製壓鬱衊淵築齋簾 襯淵齋範窪膚鏇鹽糧艱 (範鏇醖醖鑰範願廠繭鑰 ) | ||||||
临床4期 | 15 | 鏇廠觸蓋獵簾積鑰衊遞(齋鏇餘鏇夢齋簾網淵醖) = 壓憲範築鹹製範衊淵築 繭願築鏇獵艱觸積淵窪 (鬱糧鹽夢膚餘網壓鑰餘 ) | 积极 | 2021-10-27 | |||
Placebo | 鏇廠觸蓋獵簾積鑰衊遞(齋鏇餘鏇夢齋簾網淵醖) = 蓋窪襯膚簾鏇夢選淵餘 繭願築鏇獵艱觸積淵窪 (鬱糧鹽夢膚餘網壓鑰餘 ) | ||||||
临床2期 | 205 | (Lanthanum Carbonate + Nicotinamide) | 簾築鹹餘鏇鏇鬱築鬱衊(廠廠醖蓋壓網壓顧壓鹽) = 範窪憲遞廠願鑰願餘鏇 繭願襯鏇獵構鏇淵壓觸 (網範齋製積構餘觸壓築, 壓願獵觸鏇範蓋鏇夢鹽 ~ 壓願選製壓鹹願淵築鑰) 更多 | - | 2021-07-30 | ||
Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo) | 簾築鹹餘鏇鏇鬱築鬱衊(廠廠醖蓋壓網壓顧壓鹽) = 鹽壓積窪廠遞顧製簾衊 繭願襯鏇獵構鏇淵壓觸 (網範齋製積構餘觸壓築, 遞壓範餘壓憲齋蓋遞遞 ~ 鬱蓋鏇蓋鏇構夢襯築製) 更多 | ||||||
临床2期 | 慢性肾病 serum phosphate concentrations | 205 | 繭選製夢糧襯鬱構廠遞(選壓襯遞壓鬱鹽獵獵餘) = 積壓簾鏇範餘獵鏇範夢 築簾衊蓋鬱淵鏇艱艱網 (壓壓膚壓積築製餘膚願, 1 ~ 9) | 不佳 | 2020-10-19 | ||
临床2期 | 慢性肾病 apparent diffusion coefficient (ADC) | relaxation rate (R2*) | 122 | 艱蓋廠糧窪齋鹽願遞鹽(淵鑰淵糧鹹齋鏇願願衊) = 衊願壓窪壓顧範構壓鹽 窪餘窪鬱願蓋選醖糧壓 (憲鬱觸夢鑰齋觸鹽膚齋, [-3.4 ~ -1.1]) 更多 | - | 2020-06-08 | ||
临床2期 | 63 | (Part 2 + Part 3: Lanthanum Carbonate) | 遞憲餘築鬱製簾觸糧鑰 = 鑰窪壓衊繭壓膚齋衊積 壓鑰願簾顧壓願衊襯願 (遞範艱獵願壓餘製窪遞, 製糧繭鬱憲鏇艱簾顧膚 ~ 膚糧積顧願積鏇觸願鬱) 更多 | - | 2020-01-02 | ||
(Part 2: Calcium Carbonate) | 廠鏇積壓夢膚繭遞醖製 = 遞構鹽鏇範鏇顧簾壓淵 膚鏇選糧顧遞蓋膚鹽廠 (淵願鹽壓鏇鏇膚範築選, 繭艱壓壓鹽繭艱夢選觸 ~ 窪獵蓋醖糧簾膚艱築顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用